Search Results - "Seymour, J.F."

Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era by Butler, L.A, Tam, C.S, Seymour, J.F

“…Abstract The anti-CD20 antibodies represent a major advancement in the therapeutic options available for chronic lymphocytic leukemia. The addition of…”
Get full text

Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group by Ryan, G., Martinelli, G., Kuper-Hommel, M., Tsang, R., Pruneri, G., Yuen, K., Roos, D., Lennard, A., Devizzi, L., Crabb, S., Hossfeld, D., Pratt, G., Dell'Olio, M., Choo, S. P., Bociek, R. G., Radford, J., Lade, S., Gianni, A. M., Zucca, E., Cavalli, F., Seymour, J. F.

“…Background: Primary diffuse large B-cell lymphoma (DLBCL) of breast is rare. We aimed to define clinical features, prognostic factors, patterns of failure, and…”
Get full text

Stable Disease with Hematologic Improvement is Clinically Meaningful for Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine by Schuh, A.C, Döhner, H, Seymour, J.F, Turlure, P, Junghanss, C, MacWhannell, A, Tu, N, Songer, S, Beach, C.L, Dombret, H

Get full text

Impact of Gene Mutations on Survival with Azacitidine or Conventional Care Regimens (CCR) in Older Patients with Acute Myeloid Leukemia by Tang, L, Dolnik, A, MacBeth, K.J, Dombret, H, Seymour, J.F, Minden, M.D, Stone, R.M, Beach, C.L, Döhner, H, Bullinger, L

Get full text

Azacitidine Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes by Döhner, H, Vyas, P, Seymour, J.F, Santini, V, Stone, R.M, Minden, M.D, Al-Ali, H.K, del Castillo, T. Bernal, Morrill, J, Songer, S, Weaver, J, Skikne, B.S, Beach, C.L, Dombret, H

Get full text

Azacitidine Versus Conventional Care Regimens (CCR) in Elderly Patients (≥75 Years) with Acute Myeloid Leukemia (AML) in the AZA-AML-001 Study by Seymour, J.F, Buckstein, R, Santini, V, Döhner, H, Stone, R.M, Minden, M.D, Kuo, C.Y, Ben-Yehuda, D, Bargay, J, Songer, S, Weaver, J, Beach, C.L, Dombret, H

Get full text

57 A PHASE 2 MULTICENTER STUDY OF CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO FAIL TO ACHIEVE RESPONSE WITH INJECTABLE AZACITIDINE OR DECITABINE by Garcia-Manero, G, Silverman, L.R, Komrokji, R.S, Mufti, G.J, Seymour, J.F, Tsai, K, Reiser, D, Skikne, B.S, Beach, C.L, Fenaux, P

Get full text

13 THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL by Kenealy, M, Benson, W, Stevenson, W, Eek, R, Zantomio, D, Cunningham, I, Hiwase, D, Cowan, L, Vlachos, S, Zannino, D, Seymour, J.F

Get full text

Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies by Tam, C.S., Galanos, J., Seymour, J.F., Pitman, A.G., Stark, R.J., Prince, H.M.

“…Reversible posterior leukoencephalopathy syndrome (RPLS) is an uncommon but distinctive clinicoradiological entity comprising of headache, seizures, visual…”
Get full text

P-276 High doses of eltrombopag are well-tolerated in conjunction with azacitidine and demonstrate encouraging activity in patients with MDS and AML by Dickinson, M, Herbert, K, Sardjono, C, Le, T, Link, E, Zannino, D, Ruell, S, Seymour, J.F, Kenealy, M, Prince, H.M

Get full text

P-272 The combination of azacitidine and lenalidomide is deliverable without unexpected toxicity; interim safety results of the ALLG MDS4 randomised trial by Kenealy, M, Seymour, J.F, Benson, W, Stevenson, W, Eek, R, Zantomio, D, Cunningham, I, Hiwase, D, Cowan, L, Zannino, D

Get full text

176 Do genome scale methylation changes in patients with MDS treated with azacitidine and thalidomide correlate with response to treatment? by Kenealy, M, Wong, N, Maksimovic, J, Filshie, R, Seymour, J.F

Get full text

96 OVERALL SURVIVAL IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML WITH >30% BONE MARROW BLASTS AND POOR-RISK CYTOGENETICS TREATED WITH AZACITIDINE: SUBANALYSIS OF THE AZA-AML-001 STUDY by Döhner, H, Seymour, J.F, Butrym, A, Wierzbowska, A, Selleslag, D, Jang, J.H, Cavenagh, J.D, Kumar, R, Schuh, A.C, Candoni, A, Récher, C, Sandhu, I, del Castillo, T. Bernal, Al-Ali, H.K, Martinelli, G, Falantes, J, Nopenney, R, Stone, R.M, Minden, M.D, McIntyre, H, Songer, S, Lucy, L.M, Beach, C.L, Dombret, H

Get full text

124 AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML (>30% MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: SUBGROUP ANALYSIS OF THE AZA-AML-001 STUDY by Seymour, J.F, Döhner, H, Butrym, A, Wierzbowska, A, Selleslag, D, Jang, J.H, Cavenagh, J.D, Kumar, R, Schuh, A.C, Candoni, A, Récher, C, Sandhu, I, del Castillo, T. Bernal, Al-Ali, H.K, Martinelli, G, Falantes, J, Nopenney, R, Stone, R.M, Minden, M.D, McIntyre, H, Songer, S, Lucy, L.M, Beach, C.L, Dombret, H

Get full text

O01 Twenty-five years of clinical trials for adult Acute Myeloid Leukaemia (AML) in Australia by Lowenthal, R.M, Seymour, J.F

Get full text

12 Treatment of myelodysplastic syndromes with azacitidine and thalidomide by Kenealy, M.K, Seymour, J.F

Get full text

195 Biomarkers for response to lenalidomide (LEN) treatment in patients with myelodysplastic syndromes (MDS) by Burbury, K, Gambell, P, Neeson, P, Chen, K, Kenealy, M, Seymour, J.F, Prince, H.M, Westerman, D, Ritchie, D

Get full text

60 Results of a phase II study of thalidomide (Thai) and azacitidine (Aza) in patients with clinically advanced myelodysplastic syndromes (MDS) by Kenealy, M, Giri, P, Filshie, R, Ho, S.-J, Nicol, A, Cowan, L, Link, E, Seymour, J.F

Get full text

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Dreyling, M., Ghielmini, M., Rule, S., Salles, G., Ladetto, M., Tonino, S.H., Herfarth, K., Seymour, J.F., Jerkeman, M.

“…•This updated ESMO Clinical Practice Guideline provides key recommendations on the management of follicular lymphoma.•Authorship includes a multidisciplinary…”
Get full text

Central nervous system manifestations of systemic haematological malignancies and key differentials by Lasocki, A., Seymour, J.F.

“…Central nervous system (CNS) involvement by haematological malignancies is uncommon, and generally associated with a poor prognosis. Neuroimaging plays a key…”
Get full text